Next Article in Journal
Proteomics Analysis Reveals Novel RASSF2 Interaction Partners
Next Article in Special Issue
A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
Previous Article in Journal
Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy
Review

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy

Promab Biotechnologies, 2600 Hilltop Drive, Suite 320, Richmond, CA 94803, USA
*
Authors to whom correspondence should be addressed.
Academic Editor: Samuel C. Mok
Cancers 2016, 8(3), 36; https://doi.org/10.3390/cancers8030036
Received: 8 January 2016 / Revised: 7 March 2016 / Accepted: 10 March 2016 / Published: 15 March 2016
(This article belongs to the Special Issue Cancer Immunotherapies)
This review is focused on different subsets of T cells: CD4 and CD8, memory and effector functions, and their role in CAR-T therapy––a cellular adoptive immunotherapy with T cells expressing chimeric antigen receptor. The CAR-T cells recognize tumor antigens and induce cytotoxic activities against tumor cells. Recently, differences in T cell functions and the role of memory and effector T cells were shown to be important in CAR-T cell immunotherapy. The CD4+ subsets (Th1, Th2, Th9, Th17, Th22, Treg, and Tfh) and CD8+ memory and effector subsets differ in extra-cellular (CD25, CD45RO, CD45RA, CCR-7, L-Selectin [CD62L], etc.); intracellular markers (FOXP3); epigenetic and genetic programs; and metabolic pathways (catabolic or anabolic); and these differences can be modulated to improve CAR-T therapy. In addition, CD4+ Treg cells suppress the efficacy of CAR-T cell therapy, and different approaches to overcome this suppression are discussed in this review. Thus, next-generation CAR-T immunotherapy can be improved, based on our knowledge of T cell subsets functions, differentiation, proliferation, and signaling pathways to generate more active CAR-T cells against tumors. View Full-Text
Keywords: chimeric antigen receptor (CAR); immunotherapy; cancer; CD4 T cells; CD8 T cells chimeric antigen receptor (CAR); immunotherapy; cancer; CD4 T cells; CD8 T cells
Show Figures

Figure 1

MDPI and ACS Style

Golubovskaya, V.; Wu, L. Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy. Cancers 2016, 8, 36. https://doi.org/10.3390/cancers8030036

AMA Style

Golubovskaya V, Wu L. Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy. Cancers. 2016; 8(3):36. https://doi.org/10.3390/cancers8030036

Chicago/Turabian Style

Golubovskaya, Vita, and Lijun Wu. 2016. "Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy" Cancers 8, no. 3: 36. https://doi.org/10.3390/cancers8030036

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop